One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Inclusion Criteria

• •Adult participant (18 years and over)
• •* treated for one of the following conditions: RA, AS, PsA, CD, UC.
• •* either active substance naïve or treated with the originator or another biosimilar at baseline.
• •* for whom the treating physician has decided to treat by (naïve) or switch from originator or another biosimilar to Flixabi or Imraldi.
• •* participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.
• •Paediatric participants (6-17 years):
• •* treated for one of the following conditions: CD, UC.
• •* either active substance naïve or treated with another biosimilar at baseline.
• •* for whom the treating physician has decided to treat by (naïve) or switch to Flixabi (for both indications) or Imraldi (only for Crohn's disease).
• •* participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.